IL Receptor

IL Receptor製品

• All (19)
• IL Receptor阻害剤 (3)
• IL Receptor抗体(14)
• IL Receptorモジュレータ(2)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1322	Dexamethasone	Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.	Cell Host Microbe, 2024, S1931-3128(24)00005-2 Nat Commun, 2024, 15(1):7991 Nat Commun, 2024, 15(1):1176
A2012	Tocilizumab (anti-IL-6R)	Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.	Nature, 2024, 10.1038/s41586-024-08031-6 Cell Rep Med, 2024, S2666-3791(24)00195-2 J Exp Clin Cancer Res, 2024, 43(1):277
S3124	Dexamethasone Acetate	Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	STAR Protoc, 2023, 4(2):102342 Exp Mol Med, 2022, 54(9):1450-1460 iScience, 2022, 25(12):105682
S4028	Dexamethasone Sodium Phosphate	Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Cancer Cell, 2024, 42(9):1507-1527.e11 Pharmaceutics, 2022, 14(2)400 Front Oncol, 2022, 12:888695
A2011	Sarilumab (anti-IL-6Rα)	Sarilumab is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.	Biomed Pharmacother, 2024, 173:116357 Small, 2023, e2203725. Cancer Lett, 2022, 524:161-171
S8562	IRAK4-IN-2	IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades.	Cancer Lett, 2021, 503:75-90 Cancer Lett, 2021, 503:75-90
S5764	YM 90709	YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).
A2424	Anti-IL-7Ra / CD127	Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD.
A2427	Benralizumab (Anti-IL-5Ra/ CD125)	Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD.
A2431	Talacotuzumab (Anti-IL-3Ra / CD123)	Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD.
A2433	Nemolizumab (Anti-IL-31Ra)	Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD.
A2631	Anti-IL-3Ra / CD123 (SNG-CD123A)	Anti-IL-3Ra / CD123 (SNG-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD.
A2665	Anrukinzumab (Anti-IL-13)	Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD.
A2666	Anti-IL-13Ra2 / CD213a2	Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD.
A2667	Imsidolimab (Anti-IL-1RL2 / IL-36R)	Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD.
A2668	Etokimab (Anti-IL-33)	Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD.
A2669	Lusvertikimab (Anti-IL-7Ra / CD127)	Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. MW :145.64 KD.
A2107	Anti-mouse CD25 (IL-2Rα)-InVivo	The PC-61.5.3 monoclonal antibody reacts with mouse IL-2Rα also known as CD25, Ly-43, p55, or Tac.The PC-61.5.3 antibody has been shown to inhibit the binding of IL-2 to both the low and high affinity IL-2 receptor forms. Additionally, the PC-61.5.3 antibody is commonly used to deplete CD4+FoxP3+ T regulatory cells in vivo.
A2109	Anti-mouse IL-4-InVivo	The 11B11 monoclonal antibody reacts with mouse IL-4 (interleukin-4) which is a multifunctional 14 kDa cytokine.The 11B11 monoclonal antibody has been shown to neutralize the bioactivity of natural or recombinant IL-4.
S4028	Dexamethasone Sodium Phosphate	Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	Cancer Cell, 2024, 42(9):1507-1527.e11 Pharmaceutics, 2022, 14(2)400 Front Oncol, 2022, 12:888695
S8562	IRAK4-IN-2	IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades.	Cancer Lett, 2021, 503:75-90 Cancer Lett, 2021, 503:75-90
S5764	YM 90709	YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).
A2012	Tocilizumab (anti-IL-6R)	Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.	Nature, 2024, 10.1038/s41586-024-08031-6 Cell Rep Med, 2024, S2666-3791(24)00195-2 J Exp Clin Cancer Res, 2024, 43(1):277
A2011	Sarilumab (anti-IL-6Rα)	Sarilumab is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.	Biomed Pharmacother, 2024, 173:116357 Small, 2023, e2203725. Cancer Lett, 2022, 524:161-171
A2424	Anti-IL-7Ra / CD127	Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD.
A2427	Benralizumab (Anti-IL-5Ra/ CD125)	Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD.
A2431	Talacotuzumab (Anti-IL-3Ra / CD123)	Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD.
A2433	Nemolizumab (Anti-IL-31Ra)	Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD.
A2631	Anti-IL-3Ra / CD123 (SNG-CD123A)	Anti-IL-3Ra / CD123 (SNG-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD.
A2665	Anrukinzumab (Anti-IL-13)	Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD.
A2666	Anti-IL-13Ra2 / CD213a2	Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD.
A2667	Imsidolimab (Anti-IL-1RL2 / IL-36R)	Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD.
A2668	Etokimab (Anti-IL-33)	Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD.
A2669	Lusvertikimab (Anti-IL-7Ra / CD127)	Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. MW :145.64 KD.
A2107	Anti-mouse CD25 (IL-2Rα)-InVivo	The PC-61.5.3 monoclonal antibody reacts with mouse IL-2Rα also known as CD25, Ly-43, p55, or Tac.The PC-61.5.3 antibody has been shown to inhibit the binding of IL-2 to both the low and high affinity IL-2 receptor forms. Additionally, the PC-61.5.3 antibody is commonly used to deplete CD4+FoxP3+ T regulatory cells in vivo.
A2109	Anti-mouse IL-4-InVivo	The 11B11 monoclonal antibody reacts with mouse IL-4 (interleukin-4) which is a multifunctional 14 kDa cytokine.The 11B11 monoclonal antibody has been shown to neutralize the bioactivity of natural or recombinant IL-4.
S1322	Dexamethasone	Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.	Cell Host Microbe, 2024, S1931-3128(24)00005-2 Nat Commun, 2024, 15(1):7991 Nat Commun, 2024, 15(1):1176
S3124	Dexamethasone Acetate	Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.	STAR Protoc, 2023, 4(2):102342 Exp Mol Med, 2022, 54(9):1450-1460 iScience, 2022, 25(12):105682